Spine BioPharma

#ICYMI, the recording of Spine BioPharma’s presentation at the Piper Sandler 36th Annual Healthcare Conference is now available. Our CEO, Marc Viscogliosi gave an overview of: ✅ Who we are – Committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD). ✅ SB-01 – A first-in-class investigational DDD treatment offering the potential for pain relief, improved function, and potential to slow or stop disease progression. ✅ Future potential – Exploring SB-01 for additional indications beyond DDD. You can listen to the full presentation here: https://bit.ly/3BcYINV #SpineBioPharma #HealthcareInnovation #PiperSandlerConference #DegenerativeDiscDisease #SB01  

Spine BioPharma is presenting at the Piper Sandler 36th Annual Healthcare Conference on December 5th. Join us as our CEO, Marc Viscogliosi, shares insights on our innovative approach to addressing Degenerative Disc Disease (DDD) with non-opiate, non-surgical therapies. https://lnkd.in/dHC-A_AH #PiperSandlerConference #HealthcareInnovation #DegenerativeDiscDisease 

Honored to have Orthopedics This Week feature Spine BioPharma and our fully enrolled MODEL trial, a pivotal Phase 3 study for SB-01, the first intradiscal therapy targeting degenerative disc disease. This story reflects the incredible progress our team has made toward transforming the treatment options for millions of patients with chronic low back pain. Check out the article here: https://bit.ly/4evIexS #InnovationInSpineCare #DegenerativeDiscDisease 

Don’t miss Spine BioPharma’s CEO Marc Viscogliosi on November 6 at the Life Sciences Dealmaking Symposium 2024, hosted by McDermott Will & Emery Marc will be sharing valuable insights into how a strong regulatory strategy can boost deal value and mitigate risks, especially considering evolving FDA regulations. Join him and other industry leaders as they explore the future of life sciences dealmaking. Life Sciences Dealmaking Symposium 2024 #LSDS2024 #LifeSciences #Innovation #SpineBioPharma #RegulatoryStrategy #FDA #Dealmaking

We’re thrilled to announce that our Phase 3 MODEL clinical study of SB-01 has successfully enrolled over 400 patients across the U.S., marking a pivotal moment in our mission to develop non-opiate treatments for chronic low back pain. For too long, patients have faced limited options, often culminating in expensive surgeries and long recovery times. Our goal is to change that narrative and offer effective solutions that truly meet patient needs. Stay tuned for more updates! https://lnkd.in/eS--QWQg #degenerativediscdisease #ddd #lowbackpain #lowerbackpain #painmanagement #spinehealth #patientcare

Please take a few moments to view my recent presentation “Spine innovation: Have we moved the needle?", recorded live at this year’s State of Spine Surgery Think Tank in Cabo, Mexico. 11-million Americans are in front of interventional pain doctors seeking treatment with limited options. In this presentation I investigate options to prioritize innovation in Spine Surgery, including the need to close the gap between interventional physicians and spine surgeons. #spine #spinesurgery #thinktank #spinetech #spinetechnology #biotech #stateofspinesurgery #stego #innovation #lumbar #diskreplacement #medicaldevice #orthopedic #orthopedicsurgery #recovery #lowerbackpain #degenerativediscdisease #painmanagement #spinesurgeon #orthopedicspine #neurosurgery #ddd #medtech #surgicalsuccess #miniminallyinvasivesurgery #CLBP #LDDD #painrelateddisability #scoliosis # #intradiscaltreatment #lowerbackpain #interventionalspineprocedures #spinebiopharma 

We are pleased to announce that we have finalized an agreement with Ensol Biosciences Inc., to expand indications for SB-01 For Injection. We are excited about the future portfolio expansion opportunities it provides, beyond spine-related diseases. This agreement, coupled with the anticipated conclusion of the SB-01 Phase 3 MODEL Study enrollment, certainly broadens Spine BioPharma’s strategic framework considerations to address the unmet needs of patients suffering from pain related disabilities, and beyond.    Spine BioPharma is currently conducting its SB-01 Phase 3 MODEL Study (Moderate – Severe Degenerative Disc Disease Evaluation of the Lumbar Spine), the first intradiscal pharmacologic treatment to enter Phase 3 studies for the treatment of pain-related disability, associated with Degenerative Disc Disease (DDD) and anticipates completing trial enrollment of the 400-patient study in September 2024. (Clinicaltrials.gov: NCT05516992).   We would like to thank you for your continued support and look forward to the joint path ahead. We welcome any questions and feedback you may have about this update and other Spine BioPharma topics.   To view the full press release visit: https://lnkd.in/ePWyqNe6 And for additional information on Spine BioPharma , please visit www.spinebiopharma.com/ #lowerbackpain #degenerativediscdisease #painmanagement #spinesurgeon #orthopedic #orthopedicspine #neurosurgery #ddd #medtech #medicaldevice #minimiallyinvasivesurgery #CLBP #LDDD #painrelatedisability #lowbackpain #SB01 #spinedevice #spinesurgery #clinicaltrial #clinicaltrials #phase3 #spinebiopharma #lumbar #intradiscaltreatment 

Dr. Davis - thank you and your team, as well as your patients, for your continued commitment to this trial!

I’m very excited to share with you that my daughter Isabella is a part of the 2024 Student Visionaries of the Year campaign and over the next 7 weeks, she will be working to raise money and awareness for The Leukemia & Lymphoma Society (LLS) and their mission to find a cure for blood cancers. It’s an honor to be a part of this outstanding group of students, but an even larger honor to be able to work for the patients, survivors and their families. The work that LLS is doing is changing the lives of the 1.3 million Americans living with blood cancer. To learn more about why this cause is so important, watch this video: https://lnkd.in/enjJRssY There are a few ways in which we are asking for your help and support in our fundraising efforts: Donate via Isa’s personal fundraising page: https://lnkd.in/eJs-Tw-v ·      Repost and share the message & fundraising link with your contacts via email or social media ·      Help Isa secure corporate support (Corporate sponsorships are available starting at $10,000 and Program Ads for our Grand Finale can be purchased starting at $250) Thank you for your generosity and support. Your donation truly makes a difference and with your help, we’re one step closer to a cure for blood cancer. #donate #dogood #charity #nonprofit #leukemia #lymphoma #bloodcancer #cancer #cure #findthecure #survivors #LLS #cancerresearch #cancersucks #cancerawareness #hope #findacure #give #giving #support #hope #standuptocancer #gogold #americancancersociety #childhoodcancerawareness #childrenshealth #pediatriccancer #leusm #lymsm #chemo #chemotherapy #cancerfree #cancerfighter #cancersupport #treatment #curecancer #cancertreatment #love #beatcancer #cancercare #awareness #cancercommunity #cancerprevention #healthylifestyle